CYBN: Cybin Company Value to Net Income

Symbol and logo of brand Cybin (CYBN)

This chart reflects the current market value of Cybin Inc. (CYBN), a developer of psychedelic medicine, which is recorded at -4.70. The organization retains top neuroscientists through stock option programs while actively recruiting clinical trial experts. Effective management ensures trial transparency and patent protection. Unique drug formulas establish a foundation for pricing power once regulatory approvals are obtained.

CYBN (Cybin) Price to Earnings Ratio history from 07/04/2022 to 01/05/2026

Comprehensive metric breakdowns and analytics for Cybin Inc (CYBN)

- price and consensus price forecast:
Stock Price Cybin Corp|CYBN - Consensus Target
- market capitalization information:
Market Value Cybin Inc.|CYBN - Total Company Value
- balance sheet net asset value indicators:
Share Book Value Cybin|CYBN - Company Book Value|Market Capitalization to Book Value cybin.com|CYBN - Cumulative Company Assets
- company liabilities and liquidity data:
Debt to Capital Cybin Inc.|CYBN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Cybin Corp|CYBN - Company Aggregate Debts|Debt to Net Assets Ratio Cybin Inc.|CYBN - Company Long-Term Debt|Short-Term Debt Cybin|Quick Liquidity Indicator cybin.com
- net income and valuation multiples indicators:
CYBN - Net Income|Expected Net Profit Cybin Inc.|CYBN - P/E Multiple|Future Price to Earnings Cybin Corp|CYBN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Cybin Inc.|CYBN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Cybin|CYBN - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months cybin.com|CYBN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Cybin Inc.
Summary company analysis:cybin.com - CYBN
Original product of Cybin Inc.

Biotechnology platform Cybin Inc. (CYBN) is currently investing in costly clinical trials, which is temporarily suppressing operating profit. The P/E ratio compares the business's market value to its actual earnings, determining the cost of each unit of profit. For the investor, this metric serves as a gauge for expectations regarding future scalability and overvaluation risks. The dynamics of the market capitalization-to-earnings valuation clearly demonstrate the market premium for expansion potential.

Analysis of competing companies

P/E Multiple alkermes.com|Price to Earnings Ratio AVDL (Avadel Pharmaceuticals plc)|ATAI (atai Life Sciences NV) - Company Value to Net Income|Price to Earnings Ratio GH Research Corp GHRS|MNMD (Mind Medicine Corp) - Market Cap to Net Income|CMPS - Price to Earnings Ratio|Business Payback Period lbpharma.us LBRX|DRUG (Bright Minds Biosciences Inc.) - Price to Earnings Ratio|Market Cap to Earnings Vanda Pharma (VNDA)|ANRO (Alto Neuro) - P/E Multiple|Price to Earnings Ratio NRx Pharmaceuticals, Inc (NRXP)|P/E Multiple CING|SILO (Silo Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio China Pharma Holdings, Inc. CPHI|clearmindmedicine.com (CMND) - Market Cap to Earnings|Psyence Biomedical Limited - P/E Multiple|SciSparc Corp (SPRC) - Price to Earnings Ratio|SEEL (Seelos Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Virpax Pharmaceuticals, Inc. (VRPX)|KRTX (Karuna Therapeutics, Inc.) - P/E Multiple